by MarketArmor | Dec 2, 2022 | Featured
Winter 2022 could be brutal. In fact, NOAA’s Climate Prediction Center said the December-February temperature outlook depicts elevated odds of below-normal temperatures over the northern U.S., stretching from the Pacific Northwest to parts of the western Great...
by MarketArmor | Dec 2, 2022 | Featured
A selloff triggered by disappointing quarterly reports from Alphabet, Microsoft Corp, and Texas Instruments, a semiconductor maker, is signaling a market value wipeout. Despite thrilling investors during the bull market, the days of reporting earnings beyond...
by MarketArmor | Dec 2, 2022 | Featured
Apple has been under immense pressure for the better part of the year amid the broader stock market correction. While the stock has lost nearly 20% in market value year to date, the tech giant still needs to return value to shareholders. Stock buybacks have helped...
by MarketArmor | Dec 2, 2022 | Featured
Elon Musk’s acquisition of Twitter Inc. is igniting a contentious debate in the US as Democrats raise security concerns about the platform and Republicans to indicate that the Democrat’s criticism is an attempt to suppress conservative opinions. Democrats...
by MarketArmor | Nov 30, 2022 | Featured
Amazon has unveiled a new set of chips as it moves to offer high-performance computing. Graviton is the new set of chips that puts the tech giant in direct competition with long-running partners, including Intel and Nvidia. In addition, the new chips are designed to...
by MarketArmor | Nov 30, 2022 | Featured
As part of its ongoing effort to find new revenue streams, Merck & Co. has entered an agreement to pay $1.35 billion for the blood-cancer biotechnology company Imago BioSciences Inc. Merck to acquire Imago for $1.35 billion According to the agreement, Merck...
